Management of Extended-Spectrum Beta-Lactamase-Positive Gram-Negative Bacterial Urologic Infections
- Authors
- 임용관; 이미경; 김태형
- Issue Date
- 2015
- Publisher
- 대한요로생식기감염학회
- Keywords
- Extended-spectrum beta-lactamases; Urinary tract infections; Anti- bacterial agents
- Citation
- Urogenital Tract Infection, v.10, no.2, pp 84 - 91
- Pages
- 8
- Journal Title
- Urogenital Tract Infection
- Volume
- 10
- Number
- 2
- Start Page
- 84
- End Page
- 91
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/10437
- DOI
- 10.14777/uti.2015.10.2.84
- ISSN
- 2465-8243
2465-8510
- Abstract
- Extended-spectrum beta-lactamases (ESBLs) are enzymes that confer increased resistance to commonly used antibiotics. The prevalence rates of ESBL producing bacteria are increasing, and the associated increase in morbidity and mortality is becoming a public health concern. ESBL producers are emerging as an important cause of urinary tract infection (UTI) and empirical therapy should therefore be carefully selected for patients with UTI. Fosfomycin or nitrofurantoin would be an appropriate choice for empirical therapy of uncomplicated UTI. Ertapenem or cefepime might be recommended for initial empirical therapy patients suspected of having complicated UTI.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/10437)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.